Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort
Open Access
- 25 May 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (2) , 472-481
Abstract
To explore prognostic and predictive markers of SSc-associated interstitial lung disease (SSc-ILD) outcomes in a phase 3 trial (focuSSced) and prognostic markers in a real-world cohort (SMART). The focuSSced SSc-ILD subgroup included 68 of 106 placebo-treated and 68 of 104 tocilizumab-treated patients. The SMART cohort included 505 patients with SSc-ILD. Linear mixed-effect models were used to identify factors associated with change in forced vital capacity (FVC). Kaplan–Meier estimation and Cox regression were used for time-to-event analyses. In placebo-treated focuSSced patients, sex was a significant prognostic factor for FVC decline; males had increased risk for absolute decline ≥10% in percent-predicted FVC (ppFVC) and 0.22% faster weekly FVC decline than females (P = 0.0001). FVC was 9.8% lower in patients with CRP >6 mg/ml vs those with CRP ≤6 mg/ml (P = 0.0059). Tocilizumab reduced the risk for ≥10% decline in ppFVC in patients who were male, had earlier disease (P < 0.001) and 0.6% faster yearly decline (P = 0.03) than females. Prognostic markers in SSc-ILD were similar between focuSSced and SMART. Male sex and inflammatory markers were associated with lower FVC but IL-6 ≥10 pg/ml was not predictive of response to tocilizumab. ClinicalTrials.gov: NCT02453256.Keywords
Funding Information
- F. Hoffmann-La Roche Ltd
- The Royal Free Charity
- Scleroderma Research from Richard King
This publication has 30 references indexed in Scilit:
- Predictors of Mortality and Progression in Scleroderma-Associated Interstitial Lung DiseaseChest, 2014
- Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosisArthritis Research & Therapy, 2014
- IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritisBMJ Open, 2013
- Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic SclerosisThe Journal of Rheumatology, 2013
- Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosisAnnals of the Rheumatic Diseases, 2012
- Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosisClinical Rheumatology, 2010
- Changes in causes of death in systemic sclerosis, 1972–2002Annals of the Rheumatic Diseases, 2007
- Cyclophosphamide versus Placebo in Scleroderma Lung DiseaseNew England Journal of Medicine, 2006
- ESTABLISHMENT AND CHARACTERIZATION OF A HUMAN B CELL LINE FROM THE LUNG TISSUE OF A PATIENT WITH SCLERODERMA; EXTRAORDINARY HIGH LEVEL OF IL-6 SECRETION BY STIMULATED FIBROBLASTSCytokine, 2001
- In situ Expression of Cytokines and Cellular Adhesion Molecules in the Skin of Patients with Systemic SclerosisPathobiology, 1993